

Specialty Pharmacy Program

Neumega® (oprelvekin)

DESCRIPTION

Neumega is a thrombopoietic growth factor that simulates the production of platelets. Neumega is indicated for the prevention of severe thrombocytopenia and for the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.

APPROVAL DURATION

Approval duration: 1 year

APPROVAL CRITERIA

FDA-Approved Indication(s)

1. The prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.